PROCAN SR

Post-LOE

procainamide hydrochloride

Pfizer

ANDAORALTABLET, EXTENDED RELEASE

Approved

Sep 1995

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PROCAN SR (procainamide hydrochloride) by Pfizer is clinical pharmacology procainamide (pa) increases the effective refractory period of the atria, and to a lesser extent the bundle of his-purkinje system and ventricles of the heart. Approved for documented ventricular arrhythmias, such, that and 1 more indications. First approved in 1995.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Procainamide (PA) increases the effective refractory period of the atria, and to a lesser extent the bundle of His-Purkinje system and ventricles of the heart. It reduces impulse conduction velocity in the atria, His-Purkinje fibers, and ventricular muscle, but has variable…

Worked on PROCAN SR at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

PROCAN SR

Mechanism of Action

Indications (4)